Hypertension Channel
Related Channels

Precautions and Warnings With Azilsartan/Chlorthalidone

People undergoing blood pressure treatment with azilsartan/chlorthalidone should know that this medicine can increase the risk for potential complications, such as dangerously low blood pressure, electrolyte imbalances, or decreased kidney function. In addition, this medicine should not be given to people who are unable to urinate or to those with certain allergies. Other warnings and precautions with azilsartan/chlorthalidone apply to those taking certain medications.

What Should I Tell My Healthcare Provider?

You should talk with your healthcare provider prior to taking azilsartan/chlorthalidone (Edarbyclor™) if you have:
  • Kidney disease, such as kidney failure (renal failure)
  • Congestive heart failure (CHF)
  • An electrolyte imbalance, such as high or low potassium
  • Gout
  • Any allergies, including to foods, dyes, or preservatives.
In addition, let your healthcare provider know if you are:
  • Pregnant or thinking of becoming pregnant
  • Breastfeeding.
You should also tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Specific Precautions and Warnings With Azilsartan/Chlorthalidone

Some warnings and precautions to be aware of prior to taking this medication include the following:
    • Are dehydrated, which can occur if you do not drink enough fluids or have vomiting and diarrhea
    • Are on a salt-restricted diet
    • Are on kidney dialysis
    • Have heart disease, such as congestive heart failure (CHF).
  • It is important to stay hydrated by drinking plenty of fluids while taking azilsartan/chlorthalidone and let your healthcare provider know if you become dehydrated or experience dizziness, lightheadedness, or fainting.
  • Azilsartan/chlorthalidone can affect blood electrolytes, including sodium, potassium, magnesium, and calcium. Therefore, your healthcare provider may regularly check your electrolyte levels with a blood test while you take this medication. If you notice any symptoms of electrolyte imbalance, contact your healthcare provider. Symptoms may include:
    • Dry mouth
    • Feeling thirsty
    • Feeling weak
    • Extreme tiredness
    • Restlessness
    • Low blood pressure, which may cause dizziness or lightheadedness
    • Muscle tiredness, pains, or cramps
    • Nausea and vomiting
    • Decrease in urination
    • Increased heart rate (tachycardia).
  • This drug may impair kidney function, especially in people who have kidney disease or severe CHF. Your healthcare provider may choose to monitor your kidney function with a blood test while you are taking this medication. Contact your healthcare provider if you notice a decrease in urination or swelling in your hands, legs, ankles, or feet, which can be signs of kidney problems. In general, azilsartan/chlorthalidone is not recommended for use in people with severe kidney disease.
  • This medication can make gout worse. In some cases, this may be severe enough to require you to stop taking it.
  • Azilsartan/chlorthalidone is a pregnancy Category D medication. This means that it may cause harm to an unborn child (see Edarbyclor and Pregnancy). Women who take this medication should take precautions to avoid pregnancy.
  • Chlorthalidone, one of the active ingredients, passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking this medication (see Edarbyclor and Breastfeeding).
Ouch! 6 Types of Pain You Might Experience When Getting a Stent

Azilsartan/Chlorthalidone Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.